Conbercept Ophthalmic Injection

Conbercept ophthalmic injection is an anti-vascular endothelial growth factor (VEGF) drug used for neovascular (wet) age-related macular degeneration (nAMD), choroidal neovascularization (pmCNV) secondary to pathological myopia, or visual impairment secondary to diabetic macular edema (DME).
This product is a VEGF receptor-antibody recombinant fusion protein that can competitively inhibit VEGF binding to receptors and prevent the activation of VEGF family receptors, thereby inhibiting endothelial cell proliferation and angiogenesis.